The study was terminated early because of excess cardiac events. They did not find any difference in mortality or rate of progression between the two groups. Doesn’t look like a winner.
“Avosentan reduces albuminuria when added to standard treatment in people with type 2 diabetes and overt nephropathy but induces significant fluid overload and congestive heart failure.”
via Avosentan for Overt Diabetic Nephropathy — Mann et al., 10.1681/ASN.2009060593 — Journal of the American Society of Nephrology.
CKD
The development of arterial stiffness has been tied to advancing CKD, but these authors argue the contribution of reduced kidney function is not a major player.
“Although eGFR may independently predict PWV, the contribution of GFR per se does not appear to be clinically meaningful when compared with traditional cardiovascular risk factors.”
via Dominance of traditional cardiovascular risk factors over renal function in predicting arterial stiffness in subjects with chronic kidney disease — Sengstock et al. 25 (3): 853 — Nephrology Dialysis Transplantation.
CKD